Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $13.0852W HIGH $21.03
Volume
10.04 M
Value Traded
7.23 M
Short % Float
3.46%
-0.12%Week
-0.06%1 Month
-0.18%3 Month
+11.6%6 Month
-8.95%5 Year
+10.98%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
884.18 M
EPS (TTM)
1.04
P/E Ratio
16.43
Ent. Value
496.52 M
Total Shares
51.88 M
Float Shares
48.73 M
Insiders
-
Institutions
79.38%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TBPH Catalyst Timeline
Dated clinical, regulatory and corporate events for Theravance Biopharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Theravance Biopharma, Inc.
681Total events
2Upcoming
188Tier-1 (high impact)
2015 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Quarterly UpdateRevefenacinApprovedCorporate
Q2 2026 YUPELRI collaboration revenue increased 11% YoY to $20.7 million
COPDsource ↗
▲Quarterly UpdateTRELEGYCorporate
Q2 2026 TRELEGY global net sales approximately $1.0 billion
COPDsource ↗
▲Restructuring LayoffsCorporate
Organizational restructuring reduced operating expenses by 35% YoY in Q2 2026
▼Program DiscontinuationAmpreloxetineDiscontinuedCorporate
Wind-down of ampreloxetine program ongoing
◆AcquiredCorporate
Theravance Biopharma to be acquired by Zymeworks for $17.00 per share plus CVR
▲Runway Guidance UpdateCorporate
Full run-rate cost savings of ~$70M expected to materialize in Q3 2026
◆AcquisitionCorporate
Zymeworks to acquire Theravance Biopharma for $17.00 per share plus CVR
●Timing GuidancePresentation
Restructuring actions expected to be implemented over next two quarters
◆Topline ReadoutAmpreloxetineDiscontinuedClinical Data
Topline results from ampreloxetine Phase 3 CYPRESS study announced
Multiple System Atrophy (MSA) and neurogenic orthostatic hypotension (nOH)source ↗
▼Program DiscontinuationAmpreloxetineDiscontinuedCorporate
Wind down of ampreloxetine program
symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA)source ↗
▼Restructuring LayoffsCorporate
Organizational restructuring impacting ~50% of workforce; wind down of R&D and reduction in G&A
▼Primary Endpoint MissedAmpreloxetineDiscontinuedClinical Data
Phase 3 CYPRESS study did not meet primary endpoint (OHSA composite score)
symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA)source ↗
◆Timing GuidancePresentation
Strategic review accelerated; evaluating alternatives including sale of company
▼Program DiscontinuationAmpreloxetineDiscontinuedCorporate
Wind-down of ampreloxetine program ongoing
▼Trial DiscontinuedAmpreloxetineDiscontinuedTrial
Wind-down of CYPRESS clinical trial ongoing
▲Milestone PaymentTRELEGYCorporate
FY 2025 TRELEGY net sales triggered $50M milestone payment from Royalty Pharma
◆Topline ReadoutAmpreloxetineDiscontinuedClinical Data
Topline data expected from Phase 3 CYPRESS trial
symptomatic neurogenic orthostatic hypotension due to multiple system atrophysource ↗
●Quarterly UpdateCorporate
Preliminary financial results: expected cash ~$400M at end of Q1 2026; annualized cash flow ~$60-70M starting Q3 2026
▲Milestone PaymentRevefenacinApprovedCorporate
$25 million YUPELRI sales milestone received from Viatris
COPDsource ↗
◆Oral PresentationPresentation
Theravance Biopharma to participate in Oppenheimer Movers in Rare Disease Summit panel discussion
◆Oral PresentationAmpreloxetineDiscontinuedPresentation
Virtual KOL investor event to review ampreloxetine Phase 3 program ahead of topline data
symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)source ↗
◆Oral PresentationPresentation
Theravance Biopharma to participate in 8th Annual Evercore Healthcare Conference fireside chat
◆Topline ReadoutAmpreloxetineDiscontinuedClinical Data
Top-line data readout for registrational Phase 3 CYPRESS study of Ampreloxetine
nOH in MSAsource ↗
◆Milestone PaymentTRELEGYCorporate
TRELEGY sales milestone payment for 2025 net sales thresholds
COPDsource ↗
▲Enrollment CompleteAmpreloxetineDiscontinuedTrial
CYPRESS study enrollment completed
symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)source ↗
◆Oral PresentationAmpreloxetineDiscontinuedPresentation
Platform presentation on ampreloxetine for nOH in MSA at AAS 2025
symptomatic neurogenic orthostatic hypotension due to multiple system atrophysource ↗
◆Poster PresentationAmpreloxetineDiscontinuedPresentation
Poster: Enrollment strategies in a phase III trial for MSA-related nOH
symptomatic neurogenic orthostatic hypotension due to multiple system atrophysource ↗
◆Oral PresentationRevefenacinApprovedPresentation
Rapid-fire presentation: Exacerbation Rates in COPD Patients: A Retrospective Analysis of the Nebulized Once Daily Long-Acting Muscarinic Antagonist Revefenacin in a 52-Week Safety Study
COPDsource ↗
◆Oral PresentationPresentation
Theravance Biopharma management to participate in Fireside Chat at H.C. Wainwright 27th Annual Global Investment Conference
◆Enrollment CompleteAmpreloxetineDiscontinuedTrial
Enrollment completion in pivotal Phase 3 CYPRESS study expected in late summer 2025
symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)source ↗
▲Enrollment CompleteAmpreloxetineDiscontinuedTrial
Completed enrollment in open-label portion of Phase 3 CYPRESS study
symptomatic neurogenic orthostatic hypotension due to multiple system atrophysource ↗
▲Milestone PaymentRevefenacinApprovedCorporate
YUPELRI approval in China triggered $7.5 million milestone payment
COPDsource ↗
▲Enrollment CompleteAmpreloxetineDiscontinuedTrial
Completed Phase 3 CYPRESS enrollment in Q3 2025
symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)source ↗
▲Milestone PaymentRevefenacinApprovedCorporate
One-time $7.5 million milestone payment from Viatris triggered by NMPA approval
chronic obstructive pulmonary disease (COPD)source ↗
◆Enrollment MilestoneAmpreloxetineDiscontinuedTrial
Last patient enrollment in open-label portion of CYPRESS Study expected by mid-2025
symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)source ↗
▲NMPA NDA ApprovalRevefenacinApprovedEx-US Regulatory
YUPELRI (revefenacin) approved by China's NMPA for maintenance treatment of COPD
chronic obstructive pulmonary disease (COPD)source ↗
◆Enrollment CompleteAmpreloxetineDiscontinuedTrial
Nearing completion of enrollment in open label portion of CYPRESS study
symptomatic neurogenic orthostatic hypotension (nOH) associated with multiple system atrophy (MSA)source ↗
▲Partnership / LicenseCorporate
Sale of remaining royalty interest in Trelegy Ellipta to GSK for $225 million
●Last Patient Last VisitAmpreloxetineDiscontinuedTrial
Last patient enrolled in registrational Phase 3 CYPRESS study of Ampreloxetine
nOH in MSAsource ↗
◆Oral PresentationPresentation
Fireside Chat at H.C. Wainwright 3rd Annual BioConnect Investor Conference
Past FDA Catalysts and PDUFA Decisions
How TBPH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2021-12-31 | izencitinib (TD-1473) | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C50 / 100
Pipeline Score
$932M
Pipeline Value
$238M
Commercial Value
Fair Value
Valuation Signal
12
Drugs Scored
1.4x
rNPV / MCap
Theravance Biopharma, Inc. carries a moderate pipeline score (50/100), with $2.3B risk-adjusted pipeline value, led by TD-9855 in Attention-Deficit/Hyperactivity Disorder (Phase 2), across $160B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026) Revenue $104.3M x 2.3 = $238M
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TD-9855 Small moleculeCompletedNCT01693692 | Fibromyalgia | Phase 2 | COMPLETED | 392 | Apr 1, 2014 |
Clinical Trial Results
Readouts, endpoints and source filings for every TBPH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ampreloxetine Orphan | symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy | Phase 3 | 2025-10-29 | increase in norepinephrine levels, a favorable impact on blood pressure, clinically meaningful and durable symptom improvement, and no signal for worsening of supine hypertensionRead More | Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous SystemRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Farnum RhondaOfficer (SVP, COMM & MEDICAL AFFAIRS) | Sell | -3,329 223,461 held | $17.03 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TBPH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.3 % (200 %) | 6.57 M | 351.25 K | 32.89% ( 86.94 K) |
TBPH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TBPH ranks across every disease it competes in
Competitive Position is a premium feature
See how TBPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTBPH News
About Theravance Biopharma, Inc.
HeadquartersUGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, CA, KY1-1104
BIOPHARMAWATCH ELITE PLUS
Trade the next TBPH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime